Therefore, IDO inhibitors are expected to become a new strategy for the treatment of advanced MS with neurodegenerative diseases; selecting the right time point to administer IDO inhibitors and treat autoimmune diseases will be a challenge in the future. This evidence concerns the gene IDO1 and neurodegenerative disease.